Cargando…

Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab

Fibrolamellar carcinoma (FLC) is a rare cancer of the liver that most commonly affects children and young adults. There is no clear standard of care for the disease, whose response to treatment seems to be very different from that of hepatocellular carcinoma. We present a case of FLC in a patient in...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Raanan, Dinstag, Gal, Tirosh, Omer, Schiff, Eyal, Kleiner, David, Aldape, Kenneth D, Ruppin, Eytan, Beker, Tuvik, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743402/
https://www.ncbi.nlm.nih.gov/pubmed/36600603
http://dx.doi.org/10.1136/jitc-2022-005620
_version_ 1784848719274835968
author Berger, Raanan
Dinstag, Gal
Tirosh, Omer
Schiff, Eyal
Kleiner, David
Aldape, Kenneth D
Ruppin, Eytan
Beker, Tuvik
Kurzrock, Razelle
author_facet Berger, Raanan
Dinstag, Gal
Tirosh, Omer
Schiff, Eyal
Kleiner, David
Aldape, Kenneth D
Ruppin, Eytan
Beker, Tuvik
Kurzrock, Razelle
author_sort Berger, Raanan
collection PubMed
description Fibrolamellar carcinoma (FLC) is a rare cancer of the liver that most commonly affects children and young adults. There is no clear standard of care for the disease, whose response to treatment seems to be very different from that of hepatocellular carcinoma. We present a case of FLC in a patient in her mid 30s that recurred and persisted despite resection and multiple lines of treatment. Following transcriptomic analysis, a combination of ipilimumab (anti-CTLA4) and nivolumab (anti-PD-1) led to complete remission, although common biomarkers for immune checkpoint blockade were all negative in this case. The patient is still in remission. Here, combined checkpoint blockade guided by novel transcriptomic analysis led to complete remission after failure of several lines of treatment.
format Online
Article
Text
id pubmed-9743402
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-97434022022-12-13 Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab Berger, Raanan Dinstag, Gal Tirosh, Omer Schiff, Eyal Kleiner, David Aldape, Kenneth D Ruppin, Eytan Beker, Tuvik Kurzrock, Razelle J Immunother Cancer Case Report Fibrolamellar carcinoma (FLC) is a rare cancer of the liver that most commonly affects children and young adults. There is no clear standard of care for the disease, whose response to treatment seems to be very different from that of hepatocellular carcinoma. We present a case of FLC in a patient in her mid 30s that recurred and persisted despite resection and multiple lines of treatment. Following transcriptomic analysis, a combination of ipilimumab (anti-CTLA4) and nivolumab (anti-PD-1) led to complete remission, although common biomarkers for immune checkpoint blockade were all negative in this case. The patient is still in remission. Here, combined checkpoint blockade guided by novel transcriptomic analysis led to complete remission after failure of several lines of treatment. BMJ Publishing Group 2022-12-09 /pmc/articles/PMC9743402/ /pubmed/36600603 http://dx.doi.org/10.1136/jitc-2022-005620 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Case Report
Berger, Raanan
Dinstag, Gal
Tirosh, Omer
Schiff, Eyal
Kleiner, David
Aldape, Kenneth D
Ruppin, Eytan
Beker, Tuvik
Kurzrock, Razelle
Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab
title Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab
title_full Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab
title_fullStr Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab
title_full_unstemmed Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab
title_short Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab
title_sort fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743402/
https://www.ncbi.nlm.nih.gov/pubmed/36600603
http://dx.doi.org/10.1136/jitc-2022-005620
work_keys_str_mv AT bergerraanan fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab
AT dinstaggal fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab
AT tiroshomer fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab
AT schiffeyal fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab
AT kleinerdavid fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab
AT aldapekennethd fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab
AT ruppineytan fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab
AT bekertuvik fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab
AT kurzrockrazelle fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab